Wave Life Sciences Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Wave Life Sciences stock.
View analyst ratings for Wave Life Sciences or view top-rated stocks.

Wall Street analysts have given Wave Life Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Wave Life Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Wave Life Sciences saw a decline in short interest in May. As of May 28th, there was short interest totaling 2,970,000 shares, a decline of 21.2% from the May 13th total of 3,770,000 shares. Based on an average daily trading volume, of 957,300 shares, the short-interest ratio is currently 3.1 days. Approximately 8.7% of the shares of the stock are sold short.
View Wave Life Sciences' Short Interest.

Wave Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Wave Life Sciences.

Wave Life Sciences Ltd. (NASDAQ:WVE) issued its quarterly earnings data on Thursday, May, 13th. The company reported ($0.86) EPS for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.30. Wave Life Sciences had a negative net margin of 746.67% and a negative trailing twelve-month return on equity of 242.12%.
View Wave Life Sciences' earnings history.

Wave Life Sciences' stock was trading at $8.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, WVE stock has decreased by 10.0% and is now trading at $7.31.
View which stocks have been most impacted by COVID-19.

4 analysts have issued 12-month price objectives for Wave Life Sciences' stock. Their forecasts range from $7.00 to $20.00. On average, they anticipate Wave Life Sciences' share price to reach $12.00 in the next year. This suggests a possible upside of 64.2% from the stock's current price.
View analysts' price targets for Wave Life Sciences or view top-rated stocks among Wall Street analysts.

17 employees have rated Wave Life Sciences CEO Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among Wave Life Sciences' employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Wave Life Sciences include Precigen (PGEN), DiaMedica Therapeutics (DMCAF), Stoke Therapeutics (STOK), Zealand Pharma A/S (ZEAL), Avid Bioservices (CDMO), Northwest Biotherapeutics (NWBO), ImmunoGen (IMGN), Endo International (ENDP), Nurix Therapeutics (NRIX), Innoviva (INVA), Edgewise Therapeutics (EWTX), Vectura Group (VEGPF), MacroGenics (MGNX), Day One Biopharmaceuticals (DAWN) and Keros Therapeutics (KROS).
View all of WVE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Primecap Management Co. CA (9.36%), Deerfield Management Company L.P. Series C (7.03%), Maverick Capital Ltd. (6.18%), BlackRock Inc. (5.98%), Nantahala Capital Management LLC (5.78%) and JPMorgan Chase & Co. (2.58%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Gregory L Verdine, Michael A Panzara and Paul Bolno.
View institutional ownership trends for Wave Life Sciences.

WVE stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Morgan Stanley, Nantahala Capital Management LLC, D. E. Shaw & Co. Inc., Barclays PLC, Voloridge Investment Management LLC, Goldman Sachs Group Inc., and Man Group plc.
View insider buying and selling activity for Wave Life Sciences or view top insider-selling stocks.

WVE stock was purchased by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Maverick Capital Ltd., Point72 Asset Management L.P., Primecap Management Co. CA, Altium Capital Management LP, JPMorgan Chase & Co., Dimensional Fund Advisors LP, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for Wave Life Sciences or or view top insider-buying stocks.

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WVE stock can currently be purchased for approximately $7.31.

Wave Life Sciences has a market capitalization of $364.45 million and generates $20.08 million in revenue each year. The company earns $-149,910,000.00 in net income (profit) each year or ($3.82) on an earnings per share basis.

Wave Life Sciences employs 217 workers across the globe.

The official website for Wave Life Sciences is www.wavelifesciences.com.

Wave Life Sciences is headquartered at 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at (656) 236-3388 or via email at [email protected]